Coronavirus / COVID

Although there is a rise in the FLiRT family of mutations, the committee decided to seek protection against the older strain.

While much attention has been focused on the immediate risks of the virus during pregnancy, this study is focused on what happens to pregnant individuals after they have had COVID-19.

Deaths varied greatly depending on the age group, with the oldest population having the highest rates.

Research reveals a surge in pressure ulcers and in-hospital mortality rates during peak pandemic periods, prompting calls for strategies to safeguard care quality.

Recent study examines the relationship between COVID-19 vaccination and post-COVID conditions, shedding light on the potential long-term effects of vaccination.

Recent study sheds light on potential mechanisms underlying severe lung damage in COVID-19 patients.

A study shows the definitive presence of the virus long-term in individuals and could point to lingering symptoms and the possibility of Long COVID.

A new study demonstrates that for last year’s respiratory season, the difference in death rates were still much higher for COVID-19, but the gap closed significantly from the year before.

North Carolina’s senate voted to repeal the health exemption of the existing mask wearing law, thus disallowing any exceptions for people to wear a mask across the state.

A large study on the future directions unveiling COVID-19 vaccine safety and risks.

SCORPIO-HR trial findings on ensitrelvir's role in managing COVID-19 amid regulatory hurdles.

From July to November 2021, cruise ships accommodating COVID-19-vaccinated individuals implemented almost identical nonpharmaceutical protocols.

The new Equity in Antimicrobial Stewardship Efforts (EASE) is a comprehensive set of priorities designed to overcome inequities and address the challenges with prescribing practices within the minoritized populations.

This study, presented at MAD-ID, The Antimicrobial Stewardship Meeting, evaluates patients with mild COVID-19 symptoms compared to those with severe cases.

Stating low demand, the company is removing their ChAdOx1-S [recombinant] (Vaxzevria) vaccine from the market.

Investigating the long-term efficacy beyond short-term benefits.

New data from a World Health Organization (WHO) repository illustrates the treatment challenges during the acute phase of the pandemic.

According to the latest Centers for Disease Control and Prevention (CDC) data, these strains have increased in incidence rates, and now account for nearly a third of all US cases.

A study presented at ESCMID examines the efficacy and safety of the vaccine in older populations.

FDA-approves mpox vaccine, FDA grants EUA for at-home multiplex papid test, FDA grants PDUFA for GSK 5-in-1 meningococcal vaccine, and more this month from the FDA.

C-SMART trial results presented at ESCMID show a reduction of COVID-19 incidence in cancer patients.

A large study being presented at ESCMID shows the therapy was associated with a significantly lower mortality at 14-days and 28-days.

Despite the disproportionate effects of SARS-CoV-2 infection and severe outcomes on nursing home residents, less than 50% have received the updated 2023/2024 vaccine.

RedHill Biopharma said it has enrolled its first participant for the study examining the investigational therapy, RHB-107 (upamostat).

Evaluating inpatient mortality for patients without supplemental oxygen at admission across different variants of concern periods with insights from Dr. Andre Kalil.

Monika Pogorzelska-Maziarz, epidemiologist, health services researcher, and associate professor at Thomas Jefferson University, shares insights on COVID-19's influence in acute care hospitals at this year’s Society for Healthcare Epidemiology of America (SHEA) conference.

A large cohort study found this patient group more susceptible to repeat admissions, and points to potential issues associated with ambulatory care.

Comparative analysis of SARS-CoV-2 infection across pediatrics, adults, and older adults.

A small study found physical health problems lingered 1 year after their hospital stay.

New data demonstrates protection against new variants.